En español
NIDA

Quinine as a Tracer for Medication Adherence

September 19, 2016
By Eric Sarlin, M.Ed., M.A., NIDA Notes Contributing Writer

Patients who don’t take their medications or take them other than as prescribed often put themselves at risk for problems including misdiagnoses, complications, and death. The resulting costs to the U.S. health care system have been estimated at $105 billion annually. In clinical trials, patient nonadherence to medication regimens can lead to inaccurate and misleading results, potentially delaying the introduction of effective new treatments. To prevent such scenarios, clinicians and researchers need an inexpensive, reliable, and safe method of monitoring whether patients are taking their medications as directed.

Figure. Quinine Pharmacokinetics Quinine concentrations in urine were relatively consistent during a 4-day administration period and remained detectable for more than 40 hours after the last quinine dose. Oxycodone taken 2 hours after quinine did not affect quinine detection, nor did quinine affect oxycodone concentrations.
Text Description of Graphic

Dr. Shanna Babalonis and colleagues at the University of Kentucky suggest that adding low doses of quinine to patients’ medications could serve the purpose. The researchers gave nine volunteers once-daily doses of 80 milligrams of quinine for 4 days. Quinine concentrations, measured in the volunteers’ urine, remained relatively steady during quinine dosing, then decreased in the 3 days after quinine dosing was stopped (see Figure). Because quinine has a rather predictable rate of elimination, clinicians or researchers could potentially ascertain whether a patient had taken it—and the medication with which it is combined—as directed.

One class of medications that poses particular risks when used other than as prescribed is the opioids. To test whether quinine might be used specifically to monitor adherence to opioid regimens or in clinical trials enrolling opioid users, the researchers gave the volunteers, on different study days, oxycodone alone, quinine alone, and quinine combined with oxycodone. (All the volunteers were opioid users who were not addicted and not seeking treatment.) Neither the quinine nor the oxycodone behaved significantly differently when the two were given together. The finding suggests that quinine has the potential to be a safe and reliable tracer for opioid adherence or in clinical trials testing new medications for opioid use.

Although quinine produces adverse effects when used to treat malaria, the study volunteers reported no problems related to the much smaller dosage used in this study.

The researchers caution that additional studies are needed to determine whether low doses of quinine interact with other common prescription medications or with illicit drugs. Such studies could also evaluate whether quinine is a reliable marker for medication adherence in larger and more diverse patient populations.

This study was supported by NIH grant DA016718.

Source:

Babalonis, S.; Hampson, A.J.; Lofwall, M.R., et al. Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. The Journal of Clinical Pharmacology 55(12):1332-1343, 2015. Abstract

Receive articles like this in your inbox monthly!
You will only receive messages related to NIDA Notes

This page was last updated September 2016

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics

Get this Publication

    Cite this article

    APA style citation

    NIDA (). Quinine as a Tracer for Medication Adherence. Retrieved , from https://www.drugabuse.gov/news-events/nida-notes/2016/09/quinine-tracer-medication-adherence

    press ctrl+c to copy
    NIDA Notes
    Receive NIDA Notes Articles in your Email!
    You will only receive messages related to NIDA Notes